Twinbeech Capital LP Acquires New Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

Twinbeech Capital LP purchased a new position in Thermo Fisher Scientific Inc. (NYSE:TMO) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 43,621 shares of the medical research company’s stock, valued at approximately $22,693,000.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Barrett & Company Inc. purchased a new stake in shares of Thermo Fisher Scientific in the 4th quarter valued at $28,000. FPC Investment Advisory Inc. purchased a new stake in shares of Thermo Fisher Scientific in the 4th quarter worth about $28,000. Pillar Financial Advisors LLC purchased a new stake in shares of Thermo Fisher Scientific in the 4th quarter worth about $29,000. Missouri Trust & Investment Co purchased a new stake in Thermo Fisher Scientific during the 4th quarter valued at about $29,000. Finally, Endeavor Private Wealth Inc. purchased a new stake in Thermo Fisher Scientific during the 4th quarter valued at about $30,000. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Insider Transactions at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, SVP Michael A. Boxer sold 3,775 shares of the firm’s stock in a transaction on Monday, March 10th. The stock was sold at an average price of $532.52, for a total value of $2,010,263.00. Following the transaction, the senior vice president now owns 10,816 shares in the company, valued at approximately $5,759,736.32. This trade represents a 25.87% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Gianluca Pettiti sold 300 shares of Thermo Fisher Scientific stock in a transaction on Monday, April 28th. The stock was sold at an average price of $429.93, for a total value of $128,979.00. Following the transaction, the executive vice president now owns 23,167 shares in the company, valued at approximately $9,960,188.31. This represents a 1.28% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 14,075 shares of company stock valued at $7,305,942 in the last 90 days. 0.33% of the stock is currently owned by company insiders.

Thermo Fisher Scientific Price Performance

Shares of TMO stock opened at $412.15 on Monday. Thermo Fisher Scientific Inc. has a fifty-two week low of $390.50 and a fifty-two week high of $627.88. The firm has a market capitalization of $155.58 billion, a price-to-earnings ratio of 24.93, a PEG ratio of 2.99 and a beta of 0.82. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.29 and a current ratio of 1.66. The stock’s 50-day simple moving average is $453.88 and its 200-day simple moving average is $509.89.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings results on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share for the quarter, topping the consensus estimate of $5.10 by $0.05. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. The company had revenue of $10.36 billion for the quarter, compared to the consensus estimate of $10.23 billion. During the same quarter in the prior year, the company earned $5.11 EPS. Thermo Fisher Scientific’s quarterly revenue was up .2% on a year-over-year basis. As a group, equities analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, April 15th. Stockholders of record on Friday, March 14th were paid a dividend of $0.43 per share. This is a boost from Thermo Fisher Scientific’s previous quarterly dividend of $0.39. The ex-dividend date of this dividend was Friday, March 14th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.42%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 10.09%.

Analysts Set New Price Targets

A number of analysts have recently issued reports on TMO shares. Scotiabank dropped their price target on shares of Thermo Fisher Scientific from $650.00 to $605.00 and set a “sector perform” rating on the stock in a report on Friday, April 25th. Stifel Nicolaus reduced their price objective on shares of Thermo Fisher Scientific from $665.00 to $620.00 and set a “buy” rating on the stock in a research report on Thursday, April 24th. Barclays cut their target price on shares of Thermo Fisher Scientific from $620.00 to $475.00 and set an “equal weight” rating for the company in a report on Thursday, April 10th. Robert W. Baird dropped their price objective on shares of Thermo Fisher Scientific from $603.00 to $573.00 and set an “outperform” rating for the company in a research note on Thursday, April 24th. Finally, Royal Bank of Canada lowered their target price on shares of Thermo Fisher Scientific from $651.00 to $637.00 and set an “outperform” rating for the company in a research note on Thursday, April 24th. Five research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $607.43.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.